233 related articles for article (PubMed ID: 15620111)
1. Immunotherapy of tumor by targeting angiogenesis.
Hou J; Tian L; Wei Y
Sci China C Life Sci; 2004 Dec; 47(6):545-52. PubMed ID: 15620111
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenic active immunotherapy: a new approach to cancer treatment.
Pan J; Jin P; Yan J; Kabelitz D
Cancer Immunol Immunother; 2008 Aug; 57(8):1105-14. PubMed ID: 18214475
[TBL] [Abstract][Full Text] [Related]
3. Cancer immunotherapy of targeting angiogenesis.
Hou J; Tian L; Wei Y
Cell Mol Immunol; 2004 Jun; 1(3):161-6. PubMed ID: 16219162
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
5. A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy.
Kong DH; Kim MR; Jang JH; Na HJ; Lee S
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28817103
[TBL] [Abstract][Full Text] [Related]
6. [Bevacizumab (Avastin)].
Shimoyama T
Gan To Kagaku Ryoho; 2009 Mar; 36(3):523-30. PubMed ID: 19295286
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
Ferrara N; Hillan KJ; Novotny W
Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
[TBL] [Abstract][Full Text] [Related]
8. Biological response modifiers in cancer.
Reang P; Gupta M; Kohli K
MedGenMed; 2006 Nov; 8(4):33. PubMed ID: 17415315
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract][Full Text] [Related]
10. Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105.
Wood LM; Pan ZK; Guirnalda P; Tsai P; Seavey M; Paterson Y
Cancer Immunol Immunother; 2011 Jul; 60(7):931-42. PubMed ID: 21431419
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of cancer in 2012.
Kirkwood JM; Butterfield LH; Tarhini AA; Zarour H; Kalinski P; Ferrone S
CA Cancer J Clin; 2012; 62(5):309-35. PubMed ID: 22576456
[TBL] [Abstract][Full Text] [Related]
12. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
13. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
Reinacher-Schick A; Pohl M; Schmiegel W
Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435
[TBL] [Abstract][Full Text] [Related]
14. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.
Kaumaya PT; Foy KC
Future Oncol; 2012 Aug; 8(8):961-87. PubMed ID: 22894670
[TBL] [Abstract][Full Text] [Related]
15. Vaccination against angiogenesis-associated antigens: a novel cancer immunotherapy strategy.
Li Y; Bohlen P; Hicklin DJ
Curr Mol Med; 2003 Dec; 3(8):773-9. PubMed ID: 14682497
[TBL] [Abstract][Full Text] [Related]
16. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
Ferrara N
Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
[TBL] [Abstract][Full Text] [Related]
17. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.
Watanabe M; Boyer JL; Hackett NR; Qiu J; Crystal RG
Hum Gene Ther; 2008 Mar; 19(3):300-10. PubMed ID: 18324912
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis as targeted breast cancer therapy.
Hayes DF; Miller K; Sledge G
Breast; 2007 Dec; 16 Suppl 2():S17-9. PubMed ID: 17707641
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
Everson RG; Graner MW; Gromeier M; Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS; Friedman AH; Bigner DD; Sampson JH
Expert Rev Anticancer Ther; 2008 May; 8(5):717-32. PubMed ID: 18471045
[TBL] [Abstract][Full Text] [Related]
20. Promising early results for immunotherapy-antiangiogenesis combination.
Garber K
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25421345
[No Abstract] [Full Text] [Related]
[Next] [New Search]
